Plain-Language Summary
Plain-language reading of the public trial registries.
In short
- Mazdutide has a real but limited body of human research.
- 41 registered studies in total.
- 20 are still enrolling people, so this is active research, not just history.
What kind of research
- 41 studies actually gave the peptide to volunteers and measured what happened. This is the kind of study that can show whether something works.
- About 11,035 people took part in those.
How far along it is
- 15 trials have reached phase 3 or 4 — the large, late-stage trials regulators rely on to approve a drug.
- 9 have published results in the medical literature that anyone can read.
- The research spans 5 countries.
A registered trial is a plan, not a result. Registration means a study was declared in advance; it says nothing about whether the peptide worked, and a trial can be registered and then abandoned.
Filter
Showing 41 of 41 trials for Mazdutide.
Mazdutide Plus LNG-IUS for Fertility-Sparing Treatment of AEH or Early Endometrial Cancer
Tongji Hospital
Obesity · Overweight · Atypical Endometrial Hyperplasia · Endometrial Carcinoma Stage I
Mazdutide for Remission of Type 2 Diabetes: Multicentre, Double Blind, Randomised, Placebo Controlled Trial
Yanbing Li
Diabetes Mellitus, Type 2
Efficacy and Safety of Mazdutide in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Nonalcoholic Fatty Liver Disease Previously Treated With Semaglutide
Tianjin Medical University
Type 2 Diabetes Mellitus (T2DM) · Nonalcoholic Fatty Liver Disease (NAFLD) With History of Diabetes Melitus
QUARTET-DKD: Quadruple Therapy for Type 2 Diabetic Nephropathy
Huijie Zhang
Type 2 Diabetic Kidney Disease
Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME)
West China Hospital
Metabolic Dysfunction-Associated Steatohepatitis · Hepatic Steatosis · Living Liver Donors
Clinical Trials of IBI3040 in Healthy Participants and Overweight or Obese Participants
Innovent Biologics (Suzhou) Co. Ltd.
Healthy Participants · Overweight or Obese Participants
Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.
Mazdutide for Adults With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled Trial (DREAM-PRE)
Shandong Provincial Hospital
Prediabetes · Impaired Fasting Glucose · Impaired Glucose Tolerance (Prediabetes)
Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or Obesity
China National Center for Cardiovascular Diseases
Obesity & Overweight · Coronary Heart Disease
GLP-1 Therapy After Bariatric Surgery in Chinese Patients With Obesity
China-Japan Friendship Hospital
Obesity
Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity
Innovent Biologics (Suzhou) Co. Ltd.
Overweight · Obesity · Hypertensive
ASCEND-1: Lifestyle Intervention Plus Mazdutide for Weight Management
Shanghai Zhongshan Hospital
Obesity · Weight Control
A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Type 2 Diabetes
A Study of IBI362 in Chinese Adolescents With Obesity or Overweight
Innovent Biologics (Suzhou) Co. Ltd.
Adolescents With Obesity or Overweight With Weight-Related Comorbidities
Mazdutide as Adjuvant Therapy Following Sleeve Gastrectomy in Severe Obesity
Beijing Friendship Hospital
Severe Obesity
GLP-1/GCG Dual Agonist in Type 2 Diabetes With Early Dementia (LIGHT-COG Study)
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Dementia, Mild · Mild Cognitive Impairment · Type 2 Diabetes
A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Innovent Biologics (Suzhou) Co. Ltd.
Metabolic Dysfunction-associated Steatohepatitis (MASH)
Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity
Innovent Biologics (Suzhou) Co. Ltd.
Obesity
A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2
Innovent Biologics (Suzhou) Co. Ltd.
Sleep Apnea · Obstructive · Obesity
A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）
Innovent Biologics (Suzhou) Co. Ltd.
Overweight · Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)
A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity
Innovent Biologics (Suzhou) Co. Ltd.
Obesity · Heart Failure With Preserved Ejection Fraction (HFPEF) · Heart Failure With Mildly Reduced Ejection Fraction
A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder
Eli Lilly and Company
Alcohol Use Disorder
Efficacy of Mazdutide for Treating PCOS
Shanghai Zhongshan Hospital
Polycystic Ovary Syndrome
This is a Study to Evaluate the Pharmacokinetics and Safety of IBI362 in Chinese Adolescents With Obesity
Innovent Biologics (Suzhou) Co. Ltd.
Adolescents With Obesity
A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity
Innovent Biologics (Suzhou) Co. Ltd.
Type 2 Diabetes · Obesity
A Study of IBI362 9 mg in Chinese Adults With Obesity
Innovent Biologics (Suzhou) Co. Ltd.
Obesity
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
Eli Lilly and Company
Obesity · Overweight
A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight
Eli Lilly and Company
Obesity · Overweight and Obesity
Pharmacokinetics of IBI362 in Subjects With and Without Renal Impairment
Innovent Biologics (Suzhou) Co. Ltd.
Renal Impairment
A Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With Metformin, Warfarin, Atorvastatin, Digoxin in Overweight or Obese Subjects
Innovent Biologics (Suzhou) Co. Ltd.
Overweight Subjects · Obese Subjects
A Study of IBI362 in Participants With Type 2 Diabetes
Innovent Biologics (Suzhou) Co. Ltd.
Type 2 Diabetes
A Study of IBI362 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise
Innovent Biologics (Suzhou) Co. Ltd.
Type 2 Diabetes
A Study of LY3305677 in Participants With Obesity Or Overweight
Eli Lilly and Company
Overweight · Obesity
A Study of IBI362 in Participants With Obesity or Overweight
Innovent Biologics (Suzhou) Co. Ltd.
Obesity Or Overweight
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
Innovent Biologics (Suzhou) Co. Ltd.
Type 2 Diabetes
A Study of IBI362 Evaluating Weight Loss in Obese and Overweight Chinese Subjects
Innovent Biologics (Suzhou) Co. Ltd.
Overweight/ Obesity
Clinical Study of IBI362 in Healthy Chinese Male Subjects
Innovent Biologics (Suzhou) Co. Ltd.
Overweight/Obesity
Multiple-dose Tolerability and Pharmacokinetic of IBI362 in Chinese Patients With T2DM
Innovent Biologics (Suzhou) Co. Ltd.
Type 2 Diabetes
Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI362 in Overweight or Obesity Subjects
Innovent Biologics (Suzhou) Co. Ltd.
Overweight or Obesity
A Study of LY3305677 in Participants With Type 2 Diabetes
Eli Lilly and Company
Diabetes Mellitus, Type 2
A Study of Multiple Doses of LY3305677 in Healthy Participants
Eli Lilly and Company
Healthy
A Study of LY3305677 in Healthy Participants
Eli Lilly and Company
Healthy
Sources: ClinicalTrials.gov, the EU Clinical Trials Information System and ISRCTN, deduplicated so a study registered in more than one registry is counted once. A study is listed when Mazdutide is named as an intervention. A registered trial is a plan, not a result — registration says nothing about whether the peptide worked.